PRECISION BIOSCIENCES INC

DURHAM, NC · Biotech · Public

ARCUS genome editing technology platform for developing therapeutic medicines

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · precisionbiosciences.com

Sector
Biotech
Headquarters
DURHAM, NC
Latest Form D
$39.5M, Mar 2019
Total capital
$153M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$153M
3 Form D · last Mar 2019
91 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
11
29 pending · first 2025
Rank in peer group#7 of 342

Capital timeline

20152016201720182019FEDERAL ↑EQUITY ↓Cumulative $153M1st Form D$25.6M2nd Form D$88.1M3rd Form D$39.5M
20152016201720182019FEDERAL ↑EQUITY ↓Cumulative $153M1st Form D$25.6M2nd Form D$88.1M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$39.5M
  • Private capital raisedForm D · SEC · 2nd filing$88.1M
  • Private capital raisedForm D · SEC · 1st filing$25.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 342 peers

Line = median

Biotech · Platform

  • Granted patents#7 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Abid AnsariExecutive OfficerNamed in SEC Form D filings
  • BEN AUSPITZDirectorNamed in SEC Form D filings
  • Derek JantzExecutive Officer, DirectorNamed in SEC Form D filings
  • JEFF SMITHExecutive OfficerNamed in SEC Form D filings
  • Matthew KaneExecutive Officer, DirectorNamed in SEC Form D filings
  • Robert AdelmanDirectorNamed in SEC Form D filings
Show all 9 people
  • Shalini SharpDirectorNamed in SEC Form D filings
  • TODD MELBYExecutive OfficerNamed in SEC Form D filings
  • Tony YaoDirectorNamed in SEC Form D filings

What it has protected

USPTO · 11 granted of 40
Show all 40 patent records
  • Engineered Meganucleases Having Specificity For A Recognition Sequence In The Hydroxyacid Oxidase 1 GeneOct 6, 2026 · US 12,752,019Granted
  • Engineered Meganucleases Having Specificity For A Recognition Sequence In The Transthyretin GeneSep 29, 2026 · US 12,747,430Granted
  • Muscle-specific Expression CassettesSep 17, 2026 · Application 19690909Pending
  • Engineered Meganucleases Having Specificity For A Recognition Sequence In The Hepatitis B Virus GenomeSep 10, 2026 · Application 19680373Pending
  • Gene Editing Methods For Treating ALPHA-1 Antitrypsin (aat) DeficiencyAug 4, 2026 · US 12,697,400Granted
  • Engineered Nucleases That Target Human And Canine Factor Viii Genes As A Treatment For Hemophilia AJul 23, 2026 · Application 19563434Pending
  • Optimized Engineered Meganucleases Having Specificity For A Recognition Sequence In The Hepatitis B Virus GenomeJul 16, 2026 · Application 19296482Pending
  • Engineered Meganucleases With Recognition Sequences Found In The Human BETA-2 Microglobulin GeneJul 16, 2026 · Application 19317909Pending
  • Muscle-specific Expression CassettesJun 30, 2026 · US 12,668,818Granted
  • Engineered Meganucleases Having Specificity For A Recognition Sequence In The Hepatitis B Virus GenomeJun 16, 2026 · US 12,655,407Granted
  • Polypeptide Linkers For Use In Engineered MeganucleasesJun 2, 2026 · US 12,644,135Granted
  • Genetically-modified Cells Comprising A Modified Human T Cell Receptor Alpha Constant Region GeneMay 14, 2026 · Application 19214847Pending
  • Optimized Engineered Meganucleases Having Specificity For The Human T Cell Receptor Alpha Constant Region GeneApr 30, 2026 · Application 19145413Pending
  • Engineered Nucleases That Target Human And Canine Factor Viii Genes As A Treatment For Hemophilia AApr 7, 2026 · US 12,595,470Granted
  • Treatment Of Retinitis Pigmentosa Using Improved Engineered MeganucleasesApr 7, 2026 · US 12,595,469Granted
  • Antibodies And Fragments Specific For B-cell Maturation Antigen And Uses ThereofJan 29, 2026 · Application 18041118Pending
  • Engineered Meganucleases Having Specificity For A Recognition Sequence In The Hepatitis B Virus GenomeNov 13, 2025 · Application 19273915Pending
  • Optimized Engineered Nucleases Having Specificity For The Human T Cell Receptor Alpha Constant Region GeneOct 30, 2025 · Application 19029983Pending
  • Genetically-modified T Cells Comprising A Modified Intron In The T Cell Receptor Alpha GeneOct 21, 2025 · US 12,448,613Granted
  • Genetically-modified Cells Comprising A Modified Transferrin GeneOct 9, 2025 · Application 18987515Pending
  • Genetic Modification Of The Hydroxyacid Oxidase 1 Gene For Treatment Of Primary HyperoxaluriaOct 2, 2025 · Application 19232313Pending
  • Optimized Engineered Meganucleases Having Specificity For A Recognition Sequence In The Hepatitis B Virus GenomeSep 9, 2025 · US 12,410,418Granted
  • Rationally-designed Single-chain Meganucleases With Non-palindromic Recognition SequencesJul 8, 2025 · US 12,351,839Granted
  • Optimized Engineered Meganucleases Having Specificity For A Recognition Sequence In The Hepatitis B Virus GenomeMay 29, 2025 · Application 19029554Pending
  • Genetically-modified Immune Cells Comprising A Microrna-adapted Shrna (shrnamir)May 15, 2025 · Application 19029146Pending
  • Engineered Meganucleases Specific For Recognition Sequences In The Hepatitis B Virus GenomeMay 15, 2025 · Application 19029948Pending
  • Dystrophin Gene Exon Deletion Using Engineered NucleasesMay 15, 2025 · Application 19030187Pending
  • Engineered Meganucleases Specific For Recognition Sequences In The PCSK9 GeneMay 15, 2025 · Application 18898073Pending
  • Rationally-designed Single-chain Meganucleases With Non-palindromic Recognition SequencesMay 15, 2025 · Application 19029758Pending
  • Modulation Of Tgf Beta Signaling In Genetically-modified Eukaryotic CellsApr 24, 2025 · Application 18263464Pending
  • Treatment Of Retinitis Pigmentosa Using Engineered MeganucleasesApr 17, 2025 · Application 18987584Pending
  • Precise Deletion Of Chromosomal Sequences In Vivo And Treatment Of Nucleotide Repeat Expansion Disorders Using Engineered NucleasesMar 13, 2025 · Application 18770277Pending
  • Optimized Polynucleotides For Protein ExpressionFeb 27, 2025 · Application 18726955Pending
  • Methods For Cancer ImmunotherapyFeb 6, 2025 · Application 18717789Pending
  • Polynucleotides Encoding Engineered Meganucleases Having Specificity For Recognition Sequences In The Dystrophin GeneJan 30, 2025 · Application 18647877Pending
  • Methods For Cancer ImmunotherapyJan 9, 2025 · Application 18710491Pending
  • Gene Editing Methods For Treating ALPHA-1 Antitrypsin (aat) DeficiencyDec 12, 2024 · Application 18702688Pending
  • Recognition Sequences For I-crei-derived Meganucleases And Uses ThereofDec 5, 2024 · Application 18605188Pending
  • Nucleic Acids Encoding Engineered Meganucleases With Recognition Sequences Found In The Human T Cell Receptor Alpha Constant Region GeneNov 21, 2024 · Application 18793199Pending
  • Engineered Meganucleases Having Specificity For A Recognition Sequence In The Hydroxyacid Oxidase 1 GeneSep 12, 2024 · Application 18260578Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .